Sector News

Stryker announces organizational changes: Lonny J. Carpenter to retire

April 4, 2018
Life sciences

Stryker Corporation announced today that after 30 years of distinguished service, Lonny Carpenter, Group President, Global Quality and Business Operations has notified the Company of his intent to retire on March 31, 2019.

Mr. Carpenter will transfer his responsibility for Global Quality and Operations to Viju Menon, as outlined below, and retain responsibilities for our regional business operations outside of the U.S. and Asia-Pacific. He will also remain involved with our Cost Transformation for Growth program.

Mr. Carpenter began his career with Stryker in 1989 at the Instruments division where he excelled in various manufacturing and operations roles. He then proceeded to take on numerous operations and commercial business roles across the Company, including President of Medical and Group President, Instruments and Medical. In 2011, he became Group President, Global Quality and Operations and in 2014, his role was expanded to include responsibility for commercial business operations in Europe, Middle East, Africa, Canada, and Latin America.

“We are grateful for Lonny’s many contributions to Stryker’s growth and globalization efforts over the last three decades. He has been the key architect of numerous change initiatives, including our Quality Program, the establishment of our Trans-Atlantic Operating Model and Cost Transformation for Growth. He is a master collaborator and embodies our culture and values. I wish Lonny and his family all the best on his retirement,” said Kevin A. Lobo, Chairman and Chief Executive Officer.

Viju Menon will be joining Stryker as Group President, Global Quality and Operations, effective April 30, 2018. He will be responsible for running our quality, manufacturing, procurement and logistics organizations. He will work closely with Lonny to help ensure a smooth transition. “I am pleased that Viju will be joining the Stryker Leadership Team. His vast experience and technology background will complement our team and help drive Stryker’s continued growth,” said Mr. Lobo.

Mr. Menon joins us from Verizon where he served as Chief Supply Chain Officer, driving significant transformations in global sourcing and operations across all business units. Previously, in his career with Intel Corporation, Viju progressed through various leadership roles in Technology and Manufacturing and served as Head of Supply Planning Operations across Intel’s global factory network.

Mr. Menon earned dual graduate degrees (MBA and M.S. in Electrical Engineering) from the Massachusetts Institute of Technology’s Leaders for Global Operations Program. He also earned a graduate degree (M.S.E. in Computer Science Engineering) from the University of Michigan.

Source: Stryker

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend